Interplay between H6PDH and 11β-HSD1 implicated in the pathogenesis of type 2 diabetes

被引:6
|
作者
Yao, Fan [1 ]
Chen, Li [1 ,2 ]
Fan, Zheng [1 ]
Teng, Fei [1 ]
Zhao, Yali [1 ]
Guan, Fengying [1 ]
Zhang, Ming [1 ]
Liu, Yanjun [3 ]
机构
[1] Jilin Univ, Dept Pharmacol, Coll Basic Med Sci, Changchun 130021, Peoples R China
[2] Jilin Univ, Sch Nursing, Changchun 130021, Peoples R China
[3] Univ Calif Los Angeles, Sch Med, Div Endocrinol Metab & Mol Med, Charles R Drew Univ Med & Sci, Los Angeles, CA USA
基金
中国国家自然科学基金;
关键词
H6PDH; 11; beta-HSD1; Corticosterone; Liver; Type 2 diabetes mellitus; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; HEXOSE-6-PHOSPHATE DEHYDROGENASE; GLUCOCORTICOID-RECEPTOR; INSULIN-RESISTANCE; DB/DB MICE; EXPRESSION; CONTRIBUTE; OBESITY; HYPERGLYCEMIA; HEPATOCYTES;
D O I
10.1016/j.bmcl.2017.07.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Extensive studies have been performed on the role of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta-HSD1) in metabolic diseases. Our previous study reported glucose could directly regulate hexose-6-phosphate dehydrogenase (H6PDH) and 11 beta-HSD1. Recently, we further investigated the interplay of H6PDH and 11 beta-HSD1 and their roles in hepatic gluconeogenesis and insulin resistance to elucidate the importance of H6PDH and 11 beta-HSD1 in pathogenesis of type 2 diabetes mellitus (T2DM). T2DM rats model and H6PDH or 11 beta-HSD1 siRNA transfected in CBRH-7919 cells were used to explore the effect of H6PDH and 11 beta-HSD1 in T2DM. The results showed that the expression and activity of H6PDH and 11 beta-HSDI in livers of diabetic rats were increased, with the expressions of PEPCK and G6Pase or liver corticosterone increased apparently. It also showed that H6PDH siRNA and 11 beta-HSD1 siRNA could inhibit the protein expression and enzyme activity by each other. With H6PDH siRNA, the enhancement of gluconeogenesis was blocked and insulin resistance stimulated by corticosterone was reduced. H6PDH and 11 beta-HSD1 might be the effective and prospective targets for T2DM and metabolic syndromes, based on the interplay between these two enzymes. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4107 / 4113
页数:7
相关论文
共 50 条
  • [1] Cellular and genetic models of H6PDH and 11β-HSD1 function in skeletal muscle
    Zielinska, Agnieszka E.
    Fletcher, Rachel S.
    Sherlock, Mark
    Doig, Craig L.
    Lavery, Gareth G.
    CELL BIOCHEMISTRY AND FUNCTION, 2017, 35 (05) : 269 - 277
  • [2] H6PDH interacts directly with 11β-HSD1: Implications for determining the directionality of glucocorticoid catalysis
    Zhang, Yan-ling
    Zhong, Xiaotian
    Gjoka, Zheni
    Li, Yuanhong
    Stochaj, Wayne
    Stahl, Mark
    Kriz, Ron
    Tobin, James F.
    Erbe, David
    Suri, Vipin
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2009, 483 (01) : 45 - 54
  • [3] Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11β-HSD1 and H6PDH
    Abrahams, Lianne
    Semjonous, Nina M.
    Guest, Phil
    Zielinska, Agnieszka
    Hughes, Beverly
    Lavery, Gareth G.
    Stewart, Paul M.
    JOURNAL OF ENDOCRINOLOGY, 2012, 214 (03) : 367 - 372
  • [4] Increased 11β-HSD1 and H6PDH Expression in Adipose Tissue May Contribute to Glucocorticoid-induced Adipogenesis and Abdominal Obesity in Mice
    Yan, Chaoying
    Liu, Xiwen
    Navarro, Guadalupe
    Ume, Adaku
    Sims, Carl
    Lutfy, Kabir
    Friedman, Theodore
    Liu, Yanjun
    DIABETES, 2015, 64 : A550 - A550
  • [5] Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes
    Hale, Clarence
    Wang, Minghan
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (07) : 702 - 710
  • [6] H6PDH interacts directly with 11beta-HSD1: Implications for determining the directionality of glucocorticoid catalysis
    Zhang, Yan-Ling
    Zhong, Xiaotian
    Gjoka, Zheni
    Li, Yuan-Hong
    Stochaj, Wayne
    Celeste, Anthony
    Erbe, David V.
    Kriz, Ron
    Stahl, Mark
    Tobin, James F.
    DIABETES, 2007, 56 : A513 - A513
  • [7] H6PDH dependent reduction of intraluminal pyridine nucleotides supports 11beta-hsd1 activity in ER
    Czegle, I.
    Piccirella, S.
    Senesi, S.
    Csala, M.
    Mandl, J.
    Banhegyi, G.
    Fulceri, R.
    Benedetti, A.
    FEBS JOURNAL, 2006, 273 : 195 - 195
  • [8] 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease
    Anna Anderson
    Brian R. Walker
    Drugs, 2013, 73 : 1385 - 1393
  • [9] 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease
    Anderson, Anna
    Walker, Brian R.
    DRUGS, 2013, 73 (13) : 1385 - 1393
  • [10] Discovery of AMG 221: An 11β-HSD1 inhibitor in the clinic for type 2 diabetes
    Fotsch, Christopher
    Adams, Jeffrey
    Bartberger, Michael
    Bercot, Eric A.
    Cai, Lynn
    Castro, Victor M.
    Chen, Michelle
    Cupples, Rod
    Emery, Maurice
    Fretland, Jenne
    Guram, Anil
    Gustafsson, Sonja
    Hague, Andrew
    Hale, Clarence
    Han, Nianhe
    Hayashi, Michael
    Henriksson, Martin
    Hickman, Dean
    Homan, Evert
    Hungate, Randall W.
    Johansson, Lars
    Jordan, Steven
    Kaiser, Christina
    Komorowski, Renee
    Li, Aiwen
    Liu, Qingyian
    Matsumoto, Guy
    McRae, Kenneth
    Moniz, George
    Palm, Gunnar
    Pyring, David
    St. Jean, David J., Jr.
    Sun, Yaxiong
    Sydow-Backman, Mona
    Tedenborg, Lars
    Tu, Hua
    Ursa, Stephania
    Veniant, Murielle
    Williams, Meredith
    Xu, Giufen
    Ye, Qiuping
    Yuan, Chester
    Zhang, Jiandong
    Zhang, Xiping
    Wang, Minghan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237